Abstract: The invention is directed to novel synthetic C-glycolipids that selectively induce a ThI-type immune response characterized by enhanced IL-12 secretion and increased activation of dendritic cells. The compounds of the invention are thereby useful in treating infections, cancers, cell proliferative disorders, and autoimmune diseases, both directly and as adjuvants.
Type:
Grant
Filed:
May 22, 2007
Date of Patent:
November 11, 2014
Assignees:
New York University, The Aaron Diamond Aids Research Center For The City Of New York, Research Foundation Of The City University Of New York
Inventors:
Moriya Tsuji, Guangwu Chen, Richard W. Franck, Guangli Yang
Abstract: The present invention discloses a codon-optimized gene encoding major capsid protein L1 of human papilloma virus, which is capable, after transduced into a yeast cell, of efficiently expressing the major capsid protein L1 of human papilloma virus. The present invention also discloses an immunogenic macromolecule which is essentially produced by expression of said codon-optimized gene encoding the major capsid protein L1 of human papilloma virus in a yeast cell. The present invention further discloses the use of said immunogenic macromolecule and a composition comprising said immunogenic macromolecule.
Type:
Application
Filed:
June 5, 2014
Publication date:
November 6, 2014
Inventors:
Goaxia Zhang, Qiong Shen, Jianqiang Lei, Jingyu Yuan, Menghua Zhang, Qianli Zhang, Yinghua Xiong, Roger Wei, Ke Wu
Abstract: To overcome the limitations of existing particle quantification techniques, the inventors used disc centrifugation in combination with a detector, to quantify particles, in particular virus particles. Also provided is a method for determining particle density using a disc centrifuge. This method is particularly useful for determining virus particle density. Also provided is a method of estimating particle size, based on particle density.
Abstract: A BHV-1 mutant virus has been made that incorporates into a single virus two or more deletions in one or more of three genes—glycoprotein N, glycoprotein E and Us9. Specifically, a BHV-1 UL49.5?30-32 CT-null virus was made and tested. This mutant virus was then used to incorporate additional changes, e.g., the glycoprotein E cytoplasmic-tail deletion, the Us9 deletion, or both. This triple mutant BHV-1 UL49.5?30-32 CT-null/gE CT?/Us9? virus will be superior to the current BHV-1 mutants because the mutant virus will not be shed following reactivation, will be a DIVA based on gE CT-specific serum antibodies, and will induce better protective response by inducing higher SN titers and better cellular immune response. This new virus will have sufficient viral replication in the nasal epithelium and will be a good vaccine for protection of cattle from BHV-1. The new mutant viruses can also be used as vectors for exogenous genes.
Type:
Grant
Filed:
December 14, 2011
Date of Patent:
November 4, 2014
Assignee:
Board of Supervisors of Louisiana State University And Agricultural and Mechanical College
Abstract: The invention provides a composition useful to prepare influenza viruses, e.g., in the absence of helper virus, using vectors which include tandem transcription cassettes containing PolI and/or PolII promoters.
Abstract: Vaccination methods to control PCV2 infection with different PCV2 subtypes are disclosed. Specifically, a PCV2 subtype a (PCV2a) ORF2 proteins or immunogenic compositions comprising a PCV2a ORF2 protein are used in a method for the treatment or prevention of an infection with PCV2 of a different subtype, the reduction, prevention or treatment of clinical signs caused by an infection with PCV2 of a different subtype, or the prevention or treatment of a disease caused by an infection with PCV2 of a different subtype.
Type:
Application
Filed:
April 28, 2014
Publication date:
October 30, 2014
Applicant:
BOEHRINGER INGELHEIM VETMEDICA, INC.
Inventors:
Gregory HAIWICK, Luis HERNANDEZ, Wesley Scott JOHNSON, Christine Margaret MUEHLENTHALER, Eric Martin VAUGHN
Abstract: The invention provides a method of identifying an antigen from a pathogen or a disease antigen comprising the use of an adenoviral vector array comprising two or more different adenoviral vectors, wherein each adenoviral vector comprises a nucleic acid sequence encoding a different antigen of a pathogen. The adenoviral vectors are administered to antigen presenting cells (APCs) in vitro or to an animal in vivo. The immunogenicity of the antigen is measured by screening for an immune response from effector T lymphocytes in vitro and by screening for the absence of pathogen-induced disease onset in vivo.
Type:
Application
Filed:
April 19, 2013
Publication date:
October 23, 2014
Inventors:
Joseph T. Bruder, Imre Kovesdi, Duncan L. McVey, Douglas E. Brough, C. Richter King, Denise Louise Doolan, Joao Carlos Aguair, Daniel John Carucci, Martha Sedegah, Walter R. Weiss, Keith Limbach
Abstract: The present invention relates to compositions comprising replication defective Schmallenberg virus vaccines, methods of producing the vaccines, and the administration of such vaccines to animals, including ovines and bovines. The invention further relates to methods for providing long-term protective immunity against Schmallenberg in animals, including ovines and bovines.
Abstract: The present invention belongs to the field of animal health and relates to a nucleic acid sequence which comprises the genome of an infectious genotype I (EU) PRRS virus clone useful for studying Porcine Reproductive and Respiratory Syndrome (PRRS), a viral disease affecting swine, and in the development of vaccines, therapeutics and diagnostics for the prophylaxis, treatment and diagnosis of PRRS.
Abstract: The present invention relates to vaccine formulation capable of eliciting protective immune response against Chikungunya virus infection in humans and other mammalian hosts. The immunogenic formulation comprises purified inactivated Chikungunya virus in a stable formulation. Methods of propagation and purification of the virus are discussed. The inactivated virus formulation is non-infectious, immunogenic and elicits protective immune response in mammalian host. The immunogenic composition is formulated for in vivo administration to humans. The invention also discusses the strategy of developing a subunit vaccine using the recombinant viral proteins as antigens for immunization. The recombinant virus antigens that are potentially immunogenic can be used in diagnosing for the presence of the virus.
Abstract: The present invention relates to a method for the treatment or prophylaxis of a PCV2 infection or for reduction of clinical symptoms caused by or associated with a PCV2 infection in animals a) having anti-PCV2 antibodies and/or b) being young piglets of 1 to 22 days of age, comprising the step of administering an effective amount of a PCV2 antigen to that animal in need of such treatment. Preferably, those animals are pigs or young piglets.
Type:
Grant
Filed:
December 14, 2007
Date of Patent:
October 21, 2014
Assignee:
Boehringer Ingelheim Vetmedica, Inc.
Inventors:
Vicky Fachinger, Knut Elbers, Axel Lischewski, Marion Kixmoeller, Francois-Xavier Orveillon, Isabelle Freiin Von Richthofen, Michael Piontkowski
Abstract: Provided herein are helper nucleic acids comprising at least one microRNA target sequence of an endogenous, cellular microRNA and a nucleic acid encoding a viral protein, wherein the microRNA target sequence is located in the untranslated or translated region of the nucleic acid encoding the viral protein. Also provided are vector systems, compositions and cells comprising the provided helper nucleic acids and a vector or replicon. Methods of making virus-like replicon particles and populations of virus-like replicon particles (VRP) are also provided.
Type:
Application
Filed:
February 5, 2014
Publication date:
October 16, 2014
Applicant:
ALPHAVAX, INC.
Inventors:
Vernon McNeil Coffield, III, Kurt I. Kamrud, Jonathan F. Smith
Abstract: Influenza virus-like particles (VLPs) comprising the structural proteins HA, NA, M1 and M2 are described. VLPs are also generated containing M1 alone, as are VLPs with M1 and any one or two of HA, NA and M2. VLPs with HA from one influenza subtype and NA from a different influenza subtype are also described, as are VLPs in which a portion or all of HA or NA is replaced by a heterologous moiety not produced by influenza virus, so as to comprise chimeric VLPs.
Abstract: Methods of producing a pathogen with reduced replicative fitness are disclosed, as are attenuated pathogens produced using the methods. In particular examples, the method includes deoptimizing one or more codons in a coding sequence, thereby reducing the replicative fitness of the pathogen. Methods of using the attenuated pathogens as immunogenic compositions are also disclosed.
Type:
Grant
Filed:
October 7, 2005
Date of Patent:
September 30, 2014
Assignee:
The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention
Inventors:
Olen M. Kew, Cara C. Burns, Jing Shaw, Raymond Campagnoli, Jacqueline Quay
Abstract: Classical Swine Fever Virus (CSFV) E2 glycoprotein is a major inducer of neutralizing antibodies and protective immunity in swine. E2 mediates virus adsorption to the target cell, and harbors genetic determinants associated with virus virulence. CSFV E2 also contains between residues 829 and 837 a discrete epitope (TAVSPTTLR) recognized by monoclonal antibody (mAb) WH303, used to differentiate CSFV from related Pestiviruses Bovine Viral Diarrhea Virus (BVDV) and Border Disease Virus (BDV). In this report, a CSFV infectious clone of the virulent Brescia isolate (BICv) was used to progressively mutate the mAb WH303 epitope of CSFV E2 to the homologous amino acid sequence of BVDV strain NADL E2 (TSFNMDTLA).
Type:
Grant
Filed:
May 30, 2006
Date of Patent:
September 30, 2014
Assignee:
The United States of America, as Represented by the Secretary of Agriculture
Abstract: Provided herein are methods and compositions for stabilization of active agents. The active agents are distributed, mixed or embedded in a silk fibroin matrix, thereby retaining the bioactivity of the active agents upon storage and/or transportation. In some embodiments, the storage-stable vaccine-silk compositions are also provided herein.
Abstract: It is disclosed herein that treatment of a subject with an mTOR inhibitor enhances antigen-specific T cell immune responses. Thus, provided herein is a method of enhancing an antigen-specific T cell response in a subject by administering to the subject a therapeutically effective amount of an mTOR inhibitor. The antigen can be any antigen, such as an antigen from a pathogen or a vaccine, or a tumor antigen. In some embodiments, the method further comprises administering to the subject a vaccine, such as a virus vaccine or a cancer vaccine. The mTOR inhibitor can be administered either before or after vaccination to enhance the quantity and quality of the T cell immune response and immunological memory. In some examples, the mTOR inhibitor is rapamycin or a rapamycin analog.
Type:
Grant
Filed:
August 5, 2009
Date of Patent:
September 23, 2014
Assignee:
Emory University
Inventors:
Rafi Ahmed, Christian P. Larsen, Koichi Araki
Abstract: The invention provides delivery systems comprised of stabilized multilamellar vesicles, as well as compositions, methods of synthesis, and methods of use thereof. The stabilized multilamellar vesicles may comprise prophylactic, therapeutic and/or diagnostic agents.
Abstract: The present invention encompasses a cancer vaccine therapy targeting Aspartyl-[Asparaginyl]-?-hydroxylase (HAAH). The present invention contemplate bacteriophage expressing HAAH peptide fragments and methods for using said bacteriophage in methods of treating cancer.
Type:
Application
Filed:
March 15, 2013
Publication date:
September 18, 2014
Applicant:
PANACEA PHARMACEUTICALS
Inventors:
Biswajit Biswas, Carl R. Merril, Hossein A. Ghanbari
Abstract: The present invention encompasses a cancer vaccine therapy targeting Aspartyl-[Asparaginyl]-?-hydroxylase (HAAH). The present invention contemplate bacteriophage expressing HAAH peptide fragments and methods for using said bacteriophage in methods of treating cancer.
Type:
Application
Filed:
November 6, 2013
Publication date:
September 18, 2014
Applicant:
PANACEA PHARMACEUTICALS
Inventors:
Biswajit Biswas, Carl R. Merril, Hossein A. Ghanbari
Abstract: Disclosed is an attenuation method of an influenza virus, that is, a reassortant virus and a preparation method thereof. The disclosed reassortant virus has, in a ratio of 6:2, genes encoding a recombinant non-toxic protein and a wild type non-toxic protein, and genes encoding toxic proteins, HA (hemagglutinin) and NA (neuraminidase), of an influenza virus, the recombinant non-toxic protein consisting of a substituted caspase recognition sequence without a change of a protein size within the wild type non-toxic protein of the influenza virus. The disclosed attenuated influenza virus shows a high attenuation without a reduction of productivity in a fertilized egg. Accordingly, the method can be used as an economically efficient live vaccine preparation method which has both safety and efficiency and can use a fertilized egg as a production system.
Type:
Grant
Filed:
August 22, 2011
Date of Patent:
September 16, 2014
Assignee:
Industry-Academic Cooperation Foundation, Yonsei University
Inventors:
Baik Lin Seong, Yo Han Jang, Kwang Hee Lee, Young Ho Byun
Abstract: The present invention provides a nucleic acid comprises a 5? untranslated region, an NS3 protein coding region, an NS4A protein coding region, an NS4B protein coding region, an NS5A protein coding region, an NS5B protein coding region, and a 3? untranslated region of a hepatitis C virus genome, wherein the nucleic acid has nucleotide substitutions causing one or more amino acid substitutions selected from the group consisting of M(1205)K, F(1548)L, C(1615)W, T(1652)N, A(2196)T, A(2218)S, H(2223)Q, Q(2281)R, K(2520)N, and G(2374)S, as defined using the amino acid sequence shown in SEQ ID NO: 6 in the Sequence Listing as a reference sequence, in the NS3 protein coding region, the NS5A protein coding region, or the NS5B protein coding region.
Type:
Grant
Filed:
December 25, 2009
Date of Patent:
September 16, 2014
Assignees:
Toray Industries, Inc., Japan as Represented by Director-General of National Institute of Infectious Diseases, Tokyo Metropolitan Institute of Medical Science
Abstract: The present invention relates to compositions and methods for preparing cells from avian embryos. The invention also relates to cultures of such cells and the uses thereof, particularly for producing viruses such as MDV. The invention also relates to methods for the preparation of vaccines using such cells or viruses.
Type:
Application
Filed:
March 5, 2013
Publication date:
September 11, 2014
Applicant:
BIOMUNE COMPANY
Inventors:
SHARAD DEVIDASRAO SAWARKAR, CHRISTOPHER PATRICK GULLY
Abstract: The compositions and methods of the invention described herein provide treatments against Ebola virus infection by expressing gene(s) from the Ivory Coast ebolavirus (ICEBOV) species in a recombinant viral vector.
Type:
Application
Filed:
April 2, 2014
Publication date:
September 11, 2014
Applicants:
BOSTON MEDICAL CENTER CORPORATION, TRUSTEES OF BOSTON UNIVERSITY
Abstract: A composition comprising liposomes associated with a nucleic acid operatively encoding an antigenic protein and with an assistor protein, wherein the assistor protein shares at least one epitope with the antigenic protein, and wherein the nucleic acid and said assistor protein are associated with the same liposomes is described. The composition provides an improved immune response compared to mixtures of liposomes some of which are associated with the nucleic acid and some of which are associated with the assistor protein.
Type:
Grant
Filed:
November 9, 2011
Date of Patent:
September 9, 2014
Assignee:
Lipoxen Technologies Limited
Inventors:
Andrew David Bacon, Peter Laing, Gregory Gregoriadis, Wilson Romero Caparros-Wanderley
Abstract: Adjuvant and immunological vaccine compositions comprising modified, cationic metal oxides are disclosed, including methods of making modified, cationic metal oxides and methods of using the modified metal oxides in vaccine formulations and regimens.
Abstract: Disclosed are novel methods for making cochleates and cochleate compositions that include introducing a cargo moiety to a liposome in the presence of a solvent. Also disclosed are cochleates and cochleate compositions that include an aggregation inhibitor, and optionally, a cargo moiety. Additionally, anhydrous cochleates that include a protonized cargo moiety, a divalent metal cation and a negatively charge lipid are disclosed. Methods of using the cochleate compositions of the invention, including methods of administration, are also disclosed.
Type:
Application
Filed:
January 30, 2014
Publication date:
August 28, 2014
Applicant:
RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
Inventors:
Raphael J. Mannino, Susan Gould-Fogerite, Sara L. Krause-Elsmore, David Delmarre, Ruying Lu
Abstract: This document provides methods and materials involved in making and using liquid vaccine preparations for oral administration. For example, methods and materials for making and using liquid vaccine preparations for oral administration that include a lyophilized or dried vaccine component (e.g., a lyophilized pathogenic agent such as a lyophilized rotavirus preparation) and a liquid edible oil composition (e.g., a liquid edible oil composition containing one or more medium chain triglycerides) are provided. In some cases, liquid vaccine preparations that include a buffer component (e.g., CaCO3) are provided.
Abstract: The invention provides, inter alia, immunogenic compositions that comprise (a) a first antigen, (b) at least first and second adjuvants, wherein the first adjuvant comprises microparticles and wherein the second adjuvant comprises an imidazoquinoline compound, and (c) a pharmaceutically acceptable excipient, which compositions elicits an immune response when administered to a vertebrate subject. The invention also provides methods of producing immunogenic compositions and methods for using immunogenic compositions (e.g., for treatment), among other benefits.
Abstract: The invention relates to methods and related products for preventing and treating disease, based on the use of plant viral vaccines and plant viral defense strategies. The methods also involve the identification of appropriate therapeutic strategies for diseases such as cancers.
Type:
Application
Filed:
September 21, 2012
Publication date:
August 21, 2014
Applicants:
Viral Genetics, Inc., Scott & White Healthcare, The Texas A&M University System
Inventors:
Martha Karen Newell, Richard Tobin, Susannah K. Rogers
Abstract: Disclosed herein are compounds and related compositions for the treatment of viral infection, including RNA viral infection, and compounds that can modulate the RIG-I pathway in vertebrate cells, including compounds that can activate the RIG-I pathway.
Type:
Application
Filed:
September 27, 2012
Publication date:
August 14, 2014
Inventors:
Shawn P. Iadonato, Kristin Bedard, Myra Wang Imanaka, Kerry W. Fowler
Abstract: The present invention provides, among other things, methods, reagents, and systems for the treatment, detection, analysis, and/or characterization of influenza infections.
Abstract: Disclosed is a vaccine composition for transdermal administration to induce cellular immunity, comprising an antigen, wherein Th1 cell ratio in a model animal for immunological evaluation that received the composition is 10% or more.
Abstract: Peptides including an amino acid sequence of a fragment of mammalian Toll-like receptor-4 (TLR-4), analogs and derivatives thereof, and pharmaceutical compositions including these peptides. Methods for modulating a TLR-4 mediated immune response, particularly stimulating TLR-4 mediated immune response, thereby treating infectious diseases and cancer.
Abstract: The present invention discloses a codon-optimized gene encoding major capsid protein L1 of human papilloma virus, which is capable, after transduced into a yeast cell, of efficiently expressing the major capsid protein L1 of human papilloma virus. The present invention also discloses an immunogenic macromolecule which is essentially produced by expression of said codon-optimized gene encoding the major capsid protein L1 of human papilloma virus in a yeast cell. The present invention further discloses the use of said immunogenic macromolecule and a composition comprising said immunogenic macromolecule.
Type:
Grant
Filed:
November 24, 2008
Date of Patent:
August 5, 2014
Assignee:
Shanghai Zerun Biotechnology Co., Ltd.
Inventors:
Gaoxia Zhang, Qiong Shen, Jianqiang Lei, Jingyu Yuan, Menghua Zhang, Qianli Zhang, Yinghua Xiong, Roger Wei, Ke Wu
Abstract: The compositions and methods of the invention described herein provide pre- or post-exposure treatments against filovirus or arenavirus infection by expressing one or more genes (e.g., two ore more genes) from filoviruses or arenaviruses in a delivery vehicle (e.g., a recombinant viral vector or a liposome).
Type:
Grant
Filed:
December 17, 2008
Date of Patent:
August 5, 2014
Assignees:
Trustees of Boston University, Boston Medical Center Corporation
Abstract: Disclosed are a recombinant DNA molecule encoding a fusion protein comprising a SlpA chaperone and a target polypeptide wherein human FK506 binding proteins (FKBPs) are excluded as target polypeptides, a corresponding expression vector encoding said fusion protein as well as host cells transformed with said expression vector. Also disclosed are a method for producing the fusion protein, a recombinantly produced fusion protein comprising a SlpA chaperone and a target polypeptide. A further aspect of the invention is the use of the recombinantly produced fusion protein, and a reagent kit containing a recombinantly produced fusion protein comprising a SlpA chaperone and a target polypeptide.
Type:
Grant
Filed:
August 8, 2012
Date of Patent:
July 29, 2014
Assignee:
Roche Diagnostics Operations, Inc.
Inventors:
Christian Scholz, Elke Faatz, Urban Schmitt, Peter Schaarschmidt
Abstract: The invention relates to the field of PRRS viruses and infectious clones obtained from PRRS viruses. Furthermore, the invention relates to vaccines and diagnostic assays obtainable by using and modifying such infectious clones of PRRS viruses. The invention provides a porcine reproductive and respiratory syndrome virus (PRRSV) replicon having at least some of its original PRRSV nucleic acid deleted, said replicon capable of in vivo RNA replication, said replicon further having been deprived of at least some of its original PRRSV nucleic acid and/or having been supplemented with nucleic acid derived from a heterologous microorganism.
Type:
Grant
Filed:
June 8, 2006
Date of Patent:
July 29, 2014
Assignee:
Boehringer Ingelheim Vetmedica GmbH
Inventors:
Johanna Jacoba Maria Meulenberg, Monique Helene Verheije
Abstract: This invention relates to the isolation and uses of novel avian astroviruses. The present invention also relates to vaccines, kits and methods for detection of a novel astrovirus. The present invention further relates to vaccination of avians, prevention and/or treatment of avian infections associated with astrovirus. Infections of poultry by this novel astrovirus are associated with runt stunting syndromes.
Type:
Grant
Filed:
June 26, 2009
Date of Patent:
July 29, 2014
Assignee:
Biomune Company
Inventors:
Kristi Mae Dorsey, John Knox Rosenberger, Sandra Cloud Rosenberger
Abstract: The present invention relates to compositions of virus-like particles for the introduction of RNA-interference (RNAi-) inducing molecules into eukaryotic cells and methods for the cell type-specific transduction of a plurality of eukaryotic cells with RNAi-inducing molecules. The present invention furthermore relates to methods for a diagnosis, prevention and/or treatment of diseases or disease states associated with an increased expression rate of at least one endogenous gene, and/or with the undesired expression of at least one endogenous gene and/or foreign nucleic acids, in particular viral nucleic acids.
Abstract: It is an object of the present invention to provide novel and highly active cyclic-di-nucleotide (CDN) immune stimulators that activates DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides that induce STING-dependent TBK1 activation, wherein the cyclic purine dinuclotides present in the composition are substantially pure Rp,Rp or Rp,Sp stereoisomers, and particularly substantially pure Rp,Rp, or RpSp CDN thiophosphate diastereomers.
Type:
Application
Filed:
December 13, 2013
Publication date:
July 24, 2014
Applicant:
Aduro Biotech, Inc.
Inventors:
Thomas W. Dubensky, JR., David B. Kanne, Meredith Lai Ling Leong, Edward Emile Lemmens, Laura Hix Glickman
Abstract: The present invention relates to immunostimulatory oligodeoxynucleotides, vectors and vaccines comprising such oligodeoxynucleotides, to their use as a medicament, to their use in preventing or combating infectious disease, to methods for the detection of such oligodeoxynucleotides and to cells to be used in these method.
Type:
Application
Filed:
December 29, 2011
Publication date:
July 24, 2014
Inventors:
Carla Christina Schrier, Thomas Simon Ilg
Abstract: The present invention relates to the use of vaccines with adjuvants comprising cationic liposomes where neutral lipids has been incorporated into the liposomes to change the gel-liquid phase transition and thereby modifying the IgG sub-type response and enhancing the CD8 response of the liposomal adjuvant. This technology can be used to increase the production of IgG2 antibodies. This sub-type of antibodies (IgG2 in mice corresponding to IgG3 in humans) have been shown to selectively engage Fc activatory receptors on the surface of innate immune cells leading to enhanced proinflammatory responses and thereby a more efficient immune response with higher levels of protection in animal models of e.g. malaria and Chlamydia. The use of adjuvants which selectively give rise to higher levels of IgG2 antibodies will improve the effect of vaccines e.g. against intracellular infections. Furthermore the technology can be used to induce a CD8 response which has been reported to improve the effect of vaccines against e.g.
Type:
Application
Filed:
January 23, 2014
Publication date:
July 24, 2014
Applicant:
Statens Serum Institut
Inventors:
Dennis Christensen, Karen Smith Korsholm, Else Marie Agger, Peter Andersen
Abstract: The invention refers an improved vaccine against infections with pathogens, especially viral pathogens, comprising an antigen, a peptide of the formula R1—XZSZN—XZX—R2 and an immunostimulatory deoxynucleic acid containing deoxyinosine and/or deoxyuridine residues.
Type:
Grant
Filed:
April 13, 2010
Date of Patent:
July 22, 2014
Assignee:
Valneva Austria GmbH
Inventors:
Michael Buschle, André Habel, Jörg Fritz, Karin Prinz, Karen Lingnau
Abstract: The field of the invention refers to chimeric Virus Like Particles (VLP) derived from Birnavirus chimeric VP2 protein. In particular, the invention refers to chimeric VP2 fusion proteins which incorporate insertions and/or substitutions with one or more amino acids or particular peptide of interest while maintaining the capacity to assemble in the form of VLP. The invention identifies particular insertion and/or substitutions sites within VP2 P loop regions and outside said P loop regions. The invention also incorporates methods for the identification of preferred insertion and substitution sites within VP2 for the incorporation of particular amino acids and peptides of interest. The resulting chimeric VLP are of interest in the design of therapeutic and prophylactic vaccines as well as in the design of drug delivery systems, carriers for DNA and RNA in gene therapy, as targeted agents, in the development of antitoxins, and as diagnostic reagents.
Type:
Grant
Filed:
May 9, 2008
Date of Patent:
July 22, 2014
Assignee:
Chimera Pharma S.L.U
Inventors:
Thomas Zürcher, Juan José Bernal, Cayetano von Kobbe, Ignacio Jiménez Torres, Ana Diaz Blázquez, Diana Martin Lorenzo, Gloria Calderita Lucas, Arcadio Garcia de Castro
Abstract: The present invention relates to immunostimulatory oligodeoxynucleotides, vectors and vaccines comprising such oligodeoxynucleotides, to their use as a medicament, to their use in preventing or combating infectious disease, to methods for the detection of such oligodeoxynucleotides and to cells to be used in these methods.
Abstract: The invention belongs to the field of animal health and in particular Bovine Viral Diarrhea Virus (BVDV). The invention provides infectious BVDV clones and methods to produce said BVDV clones. The invention further relates to methods of attenuating said clones, attenuated BVDV clones and vaccines comprising said attenuated clones.
Type:
Grant
Filed:
February 1, 2012
Date of Patent:
July 15, 2014
Assignee:
Boehringer Ingelheim Vetmedica GmbH
Inventors:
Knut Elbers, Christiane Fetzer, Martina von Freyburg, Gregor Meyers
Abstract: The present invention relates to compositions that contain a chimeric papillomavirus virus-like particle (VLP) in combination with a DNA molecule encoding a protein or polypeptide epitope. The chimeric papillomavirus VLP is assembled from an L1 protein or polypeptide and a chimeric protein or polypeptide containing at least a portion of the L2 protein and a protein or polypeptide including an immunogenic epitope. The composition is useful for inducing an enhanced immune response against a pathogen or a tumor.
Type:
Grant
Filed:
August 30, 2007
Date of Patent:
July 15, 2014
Assignee:
University of Rochester
Inventors:
Robert C. Rose, Christine Malboeuf, Young-Eun Ellen Lee
Abstract: The present invention comprises rugged, inexpensive, reliable, and sensitive laboratory assays of antibody-based viral neutralization activity and antibody-based viral adherence inhibition activity. The assays use inactivated, fluorescently-labeled virus, allowing the tests to be performed without extensive safety precautions. The interaction of the labeled virus with target cells is monitored using flow cytometric methods. A preferred embodiment uses simple and inexpensive flow cytometry methodologies and equipment, such as bead array readers used as simplified flow cytometers. The assays are rapid, taking no longer than a few hours and are readily conducted by a trained technician. The assays are sensitive because they use labeled viruses at low concentrations and determine neutralizing and blocking capacity of sera and antibody at low concentrations. The methods are appropriate for high-throughput screening of large panels of samples.
Type:
Grant
Filed:
November 11, 2009
Date of Patent:
July 15, 2014
Assignee:
Sanofi Pasteur Vaxdesign Corp.
Inventors:
Anatoly Kachurin, Olga Kachurina, Vaughan Wittman, Tenekua Tapia